Dasatinib (Sprycel®) is an ATP-competitive inhibitor of BCR-ABL, ephrin (EPH), c-Kit, PDGFRβ, and Src family kinases and has been approved by the United States Food and Drug Administration (FDA) for the treatment of adult chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) [17]. This evidence concerns the gene PDGFRB and chronic myelogenous leukemia, BCR-ABL1 positive.